Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary consumption sector, including Nike, Li Ning, Midea Group, JD Group, Haier Smart Home, Gree Electric, Anta Sports, and many others [1]. Core Insights - The report highlights that overseas consumer earnings releases have led to stock price volatility, with A/H shares anticipating a recovery in discretionary consumption in 2026 [1]. - The performance of various sectors is analyzed, with gaming, U.S. hotels, snacks, and retail showing positive trends, while luxury goods and overseas cosmetics are experiencing declines [4][12]. - The report notes that the valuation of discretionary consumption sectors remains below the average of the past five years, indicating potential investment opportunities [10]. Sector Performance Summary - **Gaming Sector**: Increased by 5.5%, driven by strong growth in gross gaming revenue and positive earnings from major companies like MGM China [6][14]. - **U.S. Hotels**: Also up by 5.5%, with positive earnings forecasts from Marriott and Hilton [14]. - **Snacks Sector**: Rose by 3.6%, with companies like Youyou Foods and Qiaqia Foods showing strong sales growth [14]. - **Retail Sector**: Increased by 3.5%, led by Walmart and Target, which reported better-than-expected same-store sales [14]. - **Domestic Sportswear**: Grew by 2.6%, with Li Ning benefiting from its partnership with the Chinese Olympic Committee [14]. - **Credit Card Sector**: Up by 2.3%, supported by strong earnings from Visa and Mastercard [14]. - **Domestic Cosmetics**: Increased by 2.1%, benefiting from the overall strength in the beauty and skincare sector [14]. - **Luxury Goods**: Slightly up by 0.9%, influenced by a rebound in the U.S. market [14]. - **Overseas Sportswear**: Increased by 0.7%, with Nike announcing the opening of its first ACG store in Beijing [15]. - **Pet Sector**: Decreased by 0.7%, with companies like Guobao Pet and Zhongchong Co. facing declines [15]. - **Gold and Jewelry**: Down by 1.2%, affected by fluctuations in gold prices [15]. - **Overseas Cosmetics**: Fell by 5.7%, with Estée Lauder experiencing a significant drop [15].

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Revenue Performance - MGM China reported total revenue of HKD 9.62 billion in 25Q4, a year-on-year increase of 21.4%[1] - For the full year 2025, total revenue reached HKD 34.79 billion, up 10.8% year-on-year[1] EBITDA Growth - Adjusted EBITDA for 25Q4 was HKD 2.75 billion, reflecting a year-on-year increase of 29.5%[1] - The adjusted EBITDA margin improved to 28.6%, up 1.78 percentage points year-on-year[1] Gaming and Non-Gaming Contributions - Gaming revenue contributed HKD 8.46 billion, a 23.0% increase year-on-year, while non-gaming revenue was HKD 1.15 billion, up 10.9%[2] - By property, MGM Macau and MGM Cotai generated revenues of HKD 3.48 billion (+4.1% YoY) and HKD 6.14 billion (+34.1% YoY) respectively[2] Betting Trends - Total betting amount reached HKD 80.16 billion, a 9.9% increase year-on-year[3] - VIP betting increased by 5.7% to HKD 30.64 billion, while mass market betting rose by 13.2% to HKD 31.52 billion[3] Market Share and Customer Insights - MGM China's market share reached 16.5% in 25Q4, up 1.0 percentage points from 15.5% in 25Q3[5] - Management anticipates strong demand during the upcoming Chinese New Year, with robust hotel booking trends observed[6]

Investment Rating - The report assigns a positive investment rating to Coherent, indicating an expectation of outperforming the market in the next 12-18 months [19]. Core Insights - Coherent delivered an outstanding performance in FY2Q26, achieving revenue of $1.69 billion, surpassing the consensus estimate of $1.64 billion, and setting a new record high. Non-GAAP EPS reached $1.29, exceeding the market expectation of $1.20. The non-GAAP gross margin climbed to 39%, reflecting strong profitability driven by lower raw material costs and improved operational efficiency [1][8]. Summary by Relevant Sections Financial Performance - In FY2Q26, Coherent's revenue was $1.69 billion, exceeding expectations and marking a historical high. Non-GAAP EPS was $1.29, above the anticipated $1.20. The gross margin increased to 39%, benefiting from reduced raw material costs and enhanced production efficiency [1][8]. Business Segments - The data center and communications business segment accounted for over 70% of total revenue, with a revenue increase of 14% quarter-over-quarter and 36% year-over-year, driven by strong demand for 800G and 1.6T optical modules [2][9]. Order Demand - The order-to-shipment ratio for the data center business exceeded 4:1, with demand visibility at an all-time high. Orders are scheduled through the end of 2026, with significant long-term demand forecasts from major customers extending into 2028 [3][10]. Capacity Expansion - Coherent aims to double its internal InP production capacity by Q4 2026, currently achieving 80% of this target ahead of schedule. The 6-inch InP production line shows significant advantages, including a fourfold increase in chip output compared to 3-inch wafers [4][11]. Future Outlook - For FY3Q26, Coherent expects revenue between $1.7 billion and $1.84 billion, in line with market consensus. The non-GAAP gross margin is projected to be between 38.5% and 40.5%, maintaining profitability advantages. Non-GAAP EPS is anticipated to reach $1.28 to $1.48, exceeding the consensus of $1.40 [5][12].

研究报告 Research Report 6 Feb 2026 中国 & 中国 & 香港服装、鞋类及配饰设计 China (A-share) & China (Overseas) & Hong Kong Apparel, Footwear & Acc Design 中国服饰鞋类企业如何在东南亚实现海外品牌和渠道落地 Southeast Asian Apparel Industry Research: How do Chinese Apparel and Footwear Brands Realize Brand and Channel Landing in Oversea Market [Table_yemei1] 观点聚焦 Investment Focus | 股票名称 | 评级 | 股票名称 | 评级 | | --- | --- | --- | --- | | 安踏体育 | Outperform 开润股份 | | Outperform | | 安踏体育 | Outperform 健盛集团 | | Outperform | | 申洲国际 | Outperform 歌力思 | | Outperform | | ...

Investment Rating - The report maintains an "Outperform" rating for Visa, with a target price raised to US$400.60, indicating a potential upside of 21.8% from the current price of US$328.93 [2][7]. Core Insights - In 1Q FY26, Visa's total revenue reached US$15.17 billion, a year-over-year increase of 14.0%, slightly above expectations. Net revenue, after deducting client incentives, grew 14.6% to US$10.90 billion, also exceeding forecasts [3][11]. - The growth in revenue was driven by strong performance in Commercial and Money Movement Solutions (CMS) and Value-Added Services (VAS), with CMS revenue increasing by 20% year-over-year and VAS revenue up 28% year-over-year [3][11]. - Visa's stablecoin strategy has evolved into an integrated capability stack, expanding its card issuance and settlement services to over 50 countries, with stablecoin settlement volume reaching an annualized US$4.6 billion by the end of 2025 [5][12]. - Management remains optimistic about the company's outlook, maintaining full-year guidance unchanged, with projected net revenue growth of 11.3% for FY26, supported by resilient global payment trends and strong growth in CMS and VAS [7][16]. Financial Summary - For FY26, Visa expects net revenue growth of 11.3%, with diluted EPS projected to grow from US$12.93 in FY26 to US$15.94 by FY28, reflecting a sustained low double-digit growth rate [3][7]. - Operating expenses in 1Q FY26 rose by 16.2% year-over-year, influenced by unfavorable foreign exchange impacts and increased marketing expenses [3][11]. - Visa's return on equity (ROE) is projected to remain high, at 59.5% for FY26, with a price-to-earnings (P/E) ratio of 25 for the same year [2][3].

Investment Rating - The report maintains a positive outlook on Innovent Biologics, indicating an "Outperform" rating for the stock, expecting a relative return exceeding the benchmark index over the next 12-18 months [18]. Core Insights - In FY25, Innovent achieved total product revenue of approximately CNY 11.9 billion, representing a year-on-year increase of 45%, marking the first time the company surpassed the CNY 10 billion milestone [5][6]. - The oncology product portfolio has expanded to 13 products, with core products like Tyvyt® (sintilimab injection) showing steady growth and new products contributing significantly to revenue [6][10]. - The chronic disease segment has seen significant commercialization results, with products such as mazdutide (GLP-1/GCG), tafolecimab (PCSK9), and teprotumumab (IGF-1R) driving revenue growth [7][9]. - In Q4 2025, total product revenue reached approximately CNY 3.3 billion, reflecting a 60% year-on-year increase, with six new drugs included in the National Reimbursement Drug List for 2026 [8][10]. - The company is progressing towards its revenue target of CNY 20 billion by 2027, with ongoing development in oncology, metabolism, autoimmune diseases, and ophthalmology [9]. Summary by Sections Financial Performance - Total product revenue for FY25 was approximately CNY 11.9 billion, a 45% increase year-on-year [5]. - Q4 2025 revenue was approximately CNY 3.3 billion, a 60% increase year-on-year [8]. Product Development - The oncology portfolio has expanded to 13 products, with core products maintaining steady growth [6]. - Significant commercialization in chronic diseases, with key products accelerating market uptake [7]. Market Position - The company is moving closer to its revenue target of CNY 20 billion by 2027, with a rich pipeline in various therapeutic areas [9].

Group 1: Macroeconomic Marginal Changes - The consumer confidence index for January dropped significantly by 9.7 points to 84.5, the lowest level since 2014, and well below market expectations of 91 [1][6]. - November trade data returned to normal patterns, with the overall trade deficit continuing to widen, and capital goods imports increased by 7.9%, led by computers and semiconductors, indicating sustained strong investment in AI-related sectors [1][6]. - The Producer Price Index (PPI) for December rose by 0.5% month-on-month, exceeding the forecast of 0.2%, indicating that businesses are passing tariff costs downstream, with inflationary pressures persisting [1][6]. Group 2: Policy Rate Expectations - At the January FOMC meeting, the Federal Reserve maintained the benchmark interest rate at 3.5%-3.75% as expected, continuing a monthly balance sheet reduction of $40 billion [2][7]. - Powell's remarks indicated a more positive economic outlook, with a shift from moderate to more robust expansion, while the labor market remains relatively stable despite cooling [2][7]. Group 3: Warsh's Policy Stance and Potential Impact - Warsh, nominated as the next Fed Chair, is relatively hawkish, advocating for rate cuts and balance sheet reduction, viewing inflation as a choice and suggesting that AI-driven productivity gains can help curb inflation [3][8]. - His support for rate cuts without inflation concerns suggests room for further easing, but his push for balance sheet reduction may face constraints from short-term liquidity pressures and midterm election dynamics [3][8]. Group 4: Asset Implications - In the U.S. stock market, tech stocks led declines amid balance sheet reduction expectations, with significant divergence among major tech firms; Microsoft fell by 11% while Meta surged nearly 10% [4][9]. - The capital expenditures of leading companies increasingly rely on internal cash flow for financing, indicating a stronger economic pull compared to the internet bubble period [4][9]. - The steepening yield curve in U.S. Treasuries may present trading opportunities in long-term bonds, with short-to-medium term bond yields expected to decline [4][13]. - Gold prices experienced volatility due to retracting rate cut expectations, with significant market fluctuations potentially providing buying opportunities [4][16]. - The U.S. dollar may face a downward trend due to adjustments in national security strategy, with liquidity concerns contributing to short-term rebounds [5][20].

Investment Focus - The report highlights the value of consumer stocks in a volatile market, recommending a focus on companies like Guizhou Moutai, Eastroc Beverage, and Yili Group, all rated as "Outperform" [1]. Industry Overview - In January 2026, four out of eight tracked essential consumer sectors showed positive growth, including condiments, frozen foods, soft drinks, and dining, while four sectors, such as mid-to-high-end baijiu, dairy products, and beer, experienced declines [3][9]. - The overall consumer industry is characterized by a recovery in basic demand while hedonic consumption remains under pressure, indicating a shift in consumer spending towards essential goods [9]. Revenue and Growth Analysis - The revenue for the mid-to-high-end baijiu sector in January was 470 billion yuan, down 14.0% year-on-year, while the revenue for the mass-market baijiu sector was 229 billion yuan, down 3.0% year-on-year [10][11]. - The soft drink sector reported a revenue of 962 billion yuan in January, with a year-on-year growth of 1.1%, indicating a cautious recovery in demand [17]. - The frozen food sector saw a revenue of 150 billion yuan, with a year-on-year increase of 8.0%, driven by pre-Spring Festival stocking and low temperatures [16]. Price Trends - The report notes that the wholesale prices of major baijiu brands like Guizhou Moutai remained stable, while some brands faced downward price pressures due to high inventory levels [4][21]. - The average discount rates for liquid milk and condiments increased compared to the previous month, reflecting intensified market competition [35][37]. Market Dynamics - The report identifies four favorable funding factors for the essential consumer sector, including significant volatility in global capital markets, declining risk-free interest rates, increased foreign capital allocation to China, and low institutional allocation levels [6]. - The report suggests focusing on companies that align with both domestic and foreign institutional preferences, as well as those showing improvements in fundamentals and dividend yields [6].

·········································································································[Table_Title] 研究报告 Research Report 3 Feb 2026 ```··························································································································································································································································· 东南亚可选消费必需消费 Southeast Asia Discretionary Staples 东南亚指数双周报第 17 期：新马泰稳健上行，印尼承压走弱 ASEAN Index Tracking：SG, ML ...